drugset / Trial / NCT06789705
Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
RandomizedCrossoverDouble-blindTreatment
Summary
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.
Timeline
- Start
- 2025-01-27
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3,4-methylenedioxymethamphetamine | Unknown | 25 mg | — |
| Subject | 3,4-methylenedioxymethamphetamine | Unknown | 50 mg | — |